Pharsight

Qbrelis patents expiration

QBRELIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814751 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10039800 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US9463183 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(12 years from now)

Qbrelis is owned by Azurity.

Qbrelis contains Lisinopril.

Qbrelis has a total of 8 drug patents out of which 0 drug patents have expired.

Qbrelis was authorised for market use on 29 July, 2016.

Qbrelis is available in solution;oral dosage forms.

Qbrelis can be used as treatment of myocardial infarction; method of treating hypertension; treatment of heart failure; method of treatment of heart failure; reduction of mortality in acute myocardial infarction; treatment of hypertension; acute myocardial infarction, acute myocardial infarction; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; method of treatment of heart failure; treatment of heart failure; treatment of hypertension; method of treating hypertension, treatment of hypertension; method of treating hypertension; treatment of heart failure; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; acute myocardial infarction; method of treatment of heart failure.

The generics of Qbrelis are possible to be released after 06 November, 2035.

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Treatment of hypertension; Method of treating hypertension; Treatment of heart failure; Treatment of myocardial infarction; Reduction of mortality in acute myocardial infarction; Acute myocardial infa...

Dosage: SOLUTION;ORAL

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic